A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1

胶质母细胞瘤的临床适用连接特征包括肿瘤网络驱动因子 CHI3L1

阅读:5
作者:Ling Hai # ,Dirk C Hoffmann # ,Robin J Wagener ,Daniel D Azorin ,David Hausmann ,Ruifan Xie ,Magnus-Carsten Huppertz ,Julien Hiblot ,Philipp Sievers ,Sophie Heuer ,Jakob Ito ,Gina Cebulla ,Alexandros Kourtesakis ,Leon D Kaulen ,Miriam Ratliff ,Henriette Mandelbaum ,Erik Jung ,Ammar Jabali ,Sandra Horschitz ,Kati J Ernst ,Denise Reibold ,Uwe Warnken ,Varun Venkataramani ,Rainer Will ,Mario L Suvà ,Christel Herold-Mende ,Felix Sahm ,Frank Winkler ,Matthias Schlesner ,Wolfgang Wick ,Tobias Kessler

Abstract

Tumor microtubes (TMs) connect glioma cells to a network with considerable relevance for tumor progression and therapy resistance. However, the determination of TM-interconnectivity in individual tumors is challenging and the impact on patient survival unresolved. Here, we establish a connectivity signature from single-cell RNA-sequenced (scRNA-Seq) xenografted primary glioblastoma (GB) cells using a dye uptake methodology, and validate it with recording of cellular calcium epochs and clinical correlations. Astrocyte-like and mesenchymal-like GB cells have the highest connectivity signature scores in scRNA-sequenced patient-derived xenografts and patient samples. In large GB cohorts, TM-network connectivity correlates with the mesenchymal subtype and dismal patient survival. CHI3L1 gene expression serves as a robust molecular marker of connectivity and functionally influences TM networks. The connectivity signature allows insights into brain tumor biology, provides a proof-of-principle that tumor cell TM-connectivity is relevant for patients' prognosis, and serves as a robust prognostic biomarker.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。